공시 • Sep 27
Foxo Technologies Inc. Appoints Sylwia Nowak Hauman as Chief Financial Officer On September 23, 2025, FOXO Technologies Inc. appointed Sylwia Nowak Hauman (age 50) as the Company’s Chief Financial Officer (Principal Financial and Accounting Officer). Ms. Hauman has more than 25 years of finance and administrative leadership expertise in public and private multi-billion and start-up companies including extensive pharmaceutical and biotech experience from several multinational companies including Pearsanta, Aditxt (VP, Corporate Controller from May 2022 to September 2024), Lonza, Air Liquide Advanced Materials (Controller from September 2018 to August 2020), Johnson & Johnson, Accord Healthcare (Finance Director – Sales & Gross to Net from January 2020 to April 2022), and Alvogen as well as FDA regulated companies such as, Unilever and Avon. She has served as VP of Finance at Payall Payment Systems Inc. from September 2024 to the present. She has run and managed several international projects and helped design the Innovation Process Management method to successfully develop and commercialize new technologies. Ms. Hauman is a Certified Accountant, holds a Master’s degree in finance and Banking from Lodz University and is qualified in both US GAAP and IFRS. 공시 • Jun 16
FOXO Technologies Inc Announces Interim Chief Financial Officer Changes On June 13, 2025, the Board of Directors of the FOXO Technologies Inc. appointed Seamus Lagan to serve as the Company’s Interim Chief Financial Officer. On June 9, 2025, Martin Ward, the Company’s Interim Chief Financial Officer passed away unexpectedly. Mr. Lagan will be the Company’s principal financial officer and principal accounting officer on an interim basis and the Company will initiate a search for a new Chief Financial Officer. Seamus Lagan, age 56, has served as a director of the Company since September 10, 2024 and has served as the Company’s Chief Executive Officer since December 5, 2024. Mr. Lagan was appointed Chief Executive Officer and President and a director of Rennova Health Inc. (“RHI”), a company subject to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on November 2, 2015 and as Chief Executive Officer and a director of Medytox Solutions Inc., the predecessor business to a merger with RHI in 2015, and now a wholly-owned subsidiary of RHI (“Medytox”), effective September 15, 2014. Mr. Lagan served as Interim Chief Financial Officer of RHI from September 30, 2016 through May 24, 2017. He was again appointed Interim Chief Financial Officer effective October 13, 2017, and served through April 8, 2019. Mr. Lagan has also been the Interim Chief Financial Officer of RHI since May 10, 2019. Mr. Lagan has been, through Alcimede LLC until November 1, 2021 and Alcimede Limited since November 1, 2021, a consultant to Medytox since May 2011. Mr. Lagan is the managing director of Alcimede Limited, a Bahamas company that provides various consulting services, including management, organization, and financial consulting services. Mr. Lagan also currently serves, through Alcimede Limited, as chief executive officer of most of the subsidiaries of RHI and is the Chief Executive officer of the Company’s subsidiary Rennova Community Health Inc. Board Change • Feb 14
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Chairman of the Board & Member of Scientific Advisory Board Bret Barnes is the most experienced director on the board, commencing their role in 2021. Independent Director Francis deWolf was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. 공시 • Dec 24
FOXO Technologies Inc., Annual General Meeting, Dec 31, 2024 FOXO Technologies Inc., Annual General Meeting, Dec 31, 2024. 공시 • Dec 11
Foxo Technologies Inc. Appoints Seamus Lagan as Chief Executive Officer FOXO Technologies Inc. announced that Seamus Lagan has been appointed Chief Executive Officer of the Company effectively immediately. Mr. Lagan joined the Board of Directors of the Company on September 10, 2024. Seamus Lagan, age 55, has served as a director of the Company since September 10, 2024 and was appointed Chief Executive Officer and President and a director of Rennova Health Inc., in 2015, and is the Chief Executive Officer of the Company’s subsidiary, Rennova Community Health Inc. He has been an entrepreneur and investor in startup and distressed companies for over 30 years and has held numerous board and executive positions in publicly-listed companies. He has secured in excess of $100 million in funding for various projects and companies and has significant experience in mergers and acquisitions in the health care sector. Board Change • Nov 14
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 3 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Chairman of the Board & Member of Scientific Advisory Board Bret Barnes is the most experienced director on the board, commencing their role in 2021. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.